Literature DB >> 29212829

PML in a person with multiple sclerosis: Is teriflunomide the felon?

Lorena Lorefice1, Giuseppe Fenu2, Simonetta Gerevini2, Jessica Frau2, Giancarlo Coghe2, Maria Antonietta Barracciu2, Franco Contu2, Maria Giovanna Marrosu2, Eleonora Cocco2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29212829     DOI： 10.1212/WNL.0000000000004804

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

Review 1.  Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.

Authors:  Elizabeth A Mills; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

2.  A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients.

Authors:  Agnese Gugliandolo; Federica Longo; Maria Giovanna Marrosu; Giovanni Luigi Mancardi; Ilaria Gandoglia; Maurizio Melis; Fabrizio Lo Giudice; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2018-09-26       Impact factor: 2.423

3.  Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy.

Authors:  Stanley L Cohan; Keith Edwards; Lindsay Lucas; Tiffany Gervasi-Follmar; Judy O'Connor; Jessica Siuta; Vineetha Kamath; Lore Garten; Chiayi Chen; James Thomas; Kyle Smoot; Kiren Kresa-Reahl; Kateri J Spinelli
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-01-16

Review 4.  Immunological Aspects of Approved MS Therapeutics.

Authors:  Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

5.  The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide.

Authors:  Stanley Cohan; Tiffany Gervasi-Follmar; Aneesh Kamath; Vineetha Kamath; Chiayi Chen; Kyle Smoot; Elizabeth Baraban; Keith Edwards
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.